Woodridge, IL, United States
Woodridge, IL, United States

Time filter

Source Type

News Article | May 5, 2017
Site: www.businesswire.com

TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP) announced today that it has appointed Mr. Ken Yoon to the position of Chief Financial Officer. Mr. Yoon will officially join Acerus on June 1, 2017. “The Board of Directors and I are delighted to welcome Ken at this important juncture in the development of our company. He brings considerable financial acumen, transactional experience and strategic skills to the table which will be important assets as we move forward with our growth plans,” said Tom Rossi, President and Chief Executive Officer of Acerus. Mr. Yoon joins Acerus from Vive Crop Protection Inc., where he held the position of CFO and Vice President of Corporate Development as well as Corporate Secretary. While at Vive, he negotiated product license, development and IP agreements with global crop companies and was involved in raising over $35 million in capital to fund operations. Previous to his time at Vive, Mr. Yoon was with VG Private Equity Partners as their Senior Associate, Investments – Advanced Life Sciences Fund, where he identified new business opportunities for portfolio companies, including various M&A initiatives. Prior to VG Private Equity Partners, he held the position of Strategist, Entrepreneurial Business Centre (EBC) at Ernst & Young. He helped to launch the EBC and then acted as its lead for the Life Sciences sector. Mr. Yoon is a Chartered Professional Accountant. He also holds a Bachelor of Science degree from the University of Western Ontario, a Bachelor of Laws from Queen’s University and an MBA from the University of Toronto. He has been a council member of the Royal Canadian Institute for the Advancement of Science since 2009 and was awarded the Queen Elizabeth II Diamond Jubilee Medal for contribution to the Advancement of Sciences by the Government of Canada in 2012. Acerus Pharmaceuticals Corporation is a fully-integrated, Canadian specialty pharmaceutical company engaged in the development, manufacture, marketing and distribution of innovative, branded products in Men’s and Women’s Health. Acerus’ shares trade on TSX under the symbol ASP. For more information, visit www.aceruspharma.com and follow us on Twitter and LinkedIn. Information in this press release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 7, 2017 that is available at www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.


Patent
Advanced Life Sciences Inc. and Eiken Kagaku Kabushiki Kaisha | Date: 2011-04-13

The purpose is to produce, with high reproducibility, a complex of labeled probes and a carrier, said complex being to be used for detecting and measuring a target substance to be measured with high sensitivity and high stability. The means for accomplishing the purpose is that a label is bound to a probe-water soluble carrier conjugate using specific binding of an avidin compound such as avidin, streptavidin, etc. to biotin, and the binding of the avidin compound to the probe is performed before the binding to the carrier. Namely, after conjugating the avidin compound to a substance which is capable of binding to the target substance, the conjugate is bound to a high-molecule water-soluble carrier to produce a complex of the avidinized probes and the water-soluble carrier. Then the complex of the avidinized probes and the water-soluble carrier is mixed with a biotinylated label. Thus, a stable complex of the labeled probes and the water-soluble carrier, which enables the highly sensitive detection and measurement of the target substance, can be obtained with high reproducibility via the specific binding of the avidin compound to biotin.


Patent
Eiken Kagaku Kabushiki Kaisha and Advanced Life Sciences Inc. | Date: 2013-02-20

The purpose is to produce, with high reproducibility, a complex of labeled probes and a carrier, said complex being to be used for detecting and measuring a target substance to be measured with high sensitivity and high stability. The means for accomplishing the purpose is that a label is bound to a probe-water soluble carrier conjugate using specific binding of an avidin compound such as avidin, streptavidin, etc. to biotin, and the binding of the avidin compound to the probe is performed before the binding to the carrier. Namely, after conjugating the avidin compound to a substance which is capable of binding to the target substance, the conjugate is bound to a high-molecule water-soluble carrier to produce a complex of the avidinized probes and the water-soluble carrier. Then the complex of the avidinized probes and the water-soluble carrier is mixed with a biotinylated label. Thus, a stable complex of the labeled probes and the water-soluble carrier, which enables the highly sensitive detection and measurement of the target substance, can be obtained with high reproducibility via the specific binding of the avidin compound to biotin.


Patent
Advanced Life Sciences Inc. | Date: 2010-08-04

Disclosed is a novel high-sensitive ProGRP measurement method, which is free from problems such as the fluctuations in measurement values and the operational constraints (e.g., the constraints on the handling of a sample). Specifically disclosed is a method for the measurement of a gastrin-releasing peptide precursor and/or a digested product thereof using at least two different antibodies each of which can recognize an epitope represented by the amino acid sequence consisting of amino acid 47 to amino acid 68 of the amino acid sequence set forth in SEQ ID NO:1. The method can detect a ProGRP or a digested product thereof in a refrigerated sample within a shorter period, by using the sample in a smaller amount, and with a higher degree of detective sensitivity, compared with the conventional methods.


Patent
Advanced Life Sciences Inc. | Date: 2011-05-18

An HCV/GBV-B chimeric virus which maintains the replication function of HCV and is capable of infecting tamarin is disclosed in order to construct an HCV animal model which can be used as a development or evaluation system for therapeutic agents for HCV. The HCV/GBV-B chimeric RNA comprises an RNA of hepatitis C virus and an RNA of GB virus-B, wherein the RNA of hepatitis C virus comprises an RNA encoding leucine at the 1804th position and lysine at the 1966th position in the amino acid sequence of the polyprotein of hepatitis C virus.


Patent
Advanced Life Sciences Inc. | Date: 2010-02-10

The present invention provides a hepatitis C virus gene, a replicon RNA derived from the gene, a replicon-replicating cell into which the replicon RNA is introduced, and a method for screening a drug using the replicon-replicating cell. By introducing a replicon RNA comprising (A) a polynucleotide having the nucleic acid sequence shown in SEQ ID NO: 5; (B) a polynucleotide having the nucleic acid sequence shown in SEQ ID NO: 7; (C) a polynucleotide coding for a polypeptide having the amino acid sequence shown in SEQ ID NO: 6; (D) a polynucleotide coding for a polypeptide having the amino acid sequence shown in SEQ ID NO: 8; or (E) a polynucleotide having a nucleic acid sequence having a homology of not less than 90% with the nucleic acid sequence shown in SEQ ID NO: 5 or SEQ ID NO: 7; or a replicon RNA of the genotype 1b comprising nucleotides coding for the 1804th amino acid leucine and the 1966th amino acid lysine in the amino acid sequence of a hepatitis C virus polyprotein and a polynucleotide coding for an NS4B protein, into a cell, the replicon-replicating cell can be prepared. By using the replicon-replicating cell, the screening for the drug can be carried out.


Patent
Advanced Life Sciences Inc. | Date: 2011-10-07

Disclosed are an HCV gene having higher replication efficiency and higher reinfection efficiency than the known HCV gene of genotype 1b, an RNA replicon having this gene, a cell infected with this RNA replicon, which cell allows replication of HCV, and an HCV particle. The hepatitis C virus gene encodes an amino acid sequence wherein the 979th amino acid is threonine; the 1804th amino acid is leucine; and the 1966th amino acid is lysine. An HCV gene which can propagate in vitro and has higher replication efficiency and higher reinfection efficiency than the known HCV gene of genotype 1b was provided.


Patent
Advanced Life Sciences Inc. | Date: 2014-03-26

The present invention provides a hepatitis C virus gene, a replicon RNA derived from the gene, a replicon-replicating cell into which the replicon RNA is introduced, and a method for screening a drug using the replicon-replicating cell. By introducing a replicon RNA comprising (A) a polynucleotide having the nucleic acid sequence shown in SEQ ID NO: 5; (B) a polynucleotide having the nucleic acid sequence shown in SEQ ID NO: 7; (C) a polynucleotide coding for a polypeptide having the amino acid sequence shown in SEQ ID NO: 6; (D) a polynucleotide coding for a polypeptide having the amino acid sequence shown in SEQ ID NO: 8; or (E) a polynucleotide having a nucleic acid sequence having a homology of not less than 90% with the nucleic acid sequence shown in SEQ ID NO: 5 or SEQ ID NO: 7; or a replicon RNA of the genotype 1b comprising nucleotides coding for the 1804th amino acid leucine and the 1966th amino acid lysine in the amino acid sequence of a hepatitis C virus polyprotein and a polynucleotide coding for an NS4B protein, into a cell, the replicon-replicating cell can be prepared. By using the replicon-replicating cell, the screening for the drug can be carried out.


Patent
Advanced Life Sciences Inc. | Date: 2010-06-30

To provide a method for detection or quantification of hepatitis B virus (HBV) antigens in serum and a simple and highly user-friendly method for sample treatment for use in the detection or quantification thereof. The method for treatment of a sample containing hepatitis B virus (HBV) is characterized in that release of HBV antigens and disruption of antibodies that bind to HBV antigens are carried out by treating a sample containing HBV with a treatment agent containing (1) an acidifying agent and (2) a protein denaturant or an amphoteric surfactant or cationic surfactant having an alkyl group and a tertiary amine or a quaternary ammonium salt within a molecule.


Patent
Advanced Life Sciences Inc. | Date: 2013-08-14

Disclosed are an HCV gene having higher replication efficiency and higher reinfection efficiency than the known HCV gene of genotype 1b, an RNA replicon having this gene, a cell infected with this RNA replicon, which cell allows replication of HCV, and an HCV particle. The hepatitis C virus gene encodes an amino acid sequence wherein the 979th amino acid is threonine; the 1804th amino acid is leucine; and the 1966th amino acid is lysine. An HCV gene which can propagate in vitro and has higher replication efficiency and higher reinfection efficiency than the known HCV gene of genotype 1b was provided.

Loading Advanced Life Sciences Inc. collaborators
Loading Advanced Life Sciences Inc. collaborators